1 stories
AI briefings + tags; source links are the ground truth.
About
🇧🇷
Brazil
G1 (PT)
Life & Tech
New oral GLP-1 reduces more glucose and weight than semaglutide in phase 3 study; Orforgliprona increases weight loss by 73%
The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.
Feb 26 • 16:48 UTC